DNMT3B and acute myeloid leukemia: Furthermore, in the AML02 cohort, DNMT3B expression associated with the expression of 41 of the 50 genes associated with clinical outcome in the initial CC-PROMISE analysis (p ≤ 0.05; Supplementary Table 3 and Supplementary Figure 6); suggesting that DNMT3B may epigenetically regulate the expression of these genes that may be especially relevant to AML prognosis.